New and Emerging Therapies for Pediatric Atopic Dermatitis

Henry L. Nguyen, Katelyn R. Anderson, Megha M. Tollefson

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.

Original languageEnglish (US)
Pages (from-to)239-260
Number of pages22
JournalPediatric Drugs
Issue number4
StatePublished - Aug 1 2019

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)


Dive into the research topics of 'New and Emerging Therapies for Pediatric Atopic Dermatitis'. Together they form a unique fingerprint.

Cite this